Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference

Astria Therapeutics, Inc. (NASDAQ: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming virtual Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th at 9:20am ET.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/oppenheimer33/atxs/2815552. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  218.89
-3.14 (-1.41%)
AAPL  258.74
-4.03 (-1.53%)
AMD  228.87
-9.16 (-3.85%)
BAC  50.96
-0.56 (-1.09%)
GOOG  252.42
+1.08 (0.43%)
META  730.86
-2.41 (-0.33%)
MSFT  523.55
+5.89 (1.14%)
NVDA  179.14
-2.02 (-1.12%)
ORCL  271.24
-3.91 (-1.42%)
TSLA  434.38
-8.23 (-1.86%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.